We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
Read MoreHide Full Article
We expect Vertex Pharmaceuticals Incorporated (VRTX - Free Report) to surpass expectations when it reports third-quarter 2020 results on Oct 29, after the market closes.
The company’s surprise record is pretty impressive with an earnings beat in each of the trailing four quarters, the average being 27.71%. In the last reported quarter, Vertex delivered an earnings surprise of 22.54%.
Shares of Vertex have lost 3.3% in the year so far compared with the industry’s 2.8% decrease.
Let’s see, how things are shaping up for the quarter to be reported.
Factors at Play
Revenue growth in the last reported quarter was driven by a rapid uptake of the company’s newly-launched cystic fibrosis (CF) medicine Trikafta, a trend that most likely continued in the third quarter as well.
Notably, first-half sales of Trikafta benefited from some early refills by patients amid COVID-19-led disruptions. This increased patient inventory is likely to have normalized in the third quarter. Also, the pace of new patient initiations of Trikafta might have slowed in the third quarter as a high percentage of currently eligible patients is already on Trikafta. Investors will be keen to know the sales numbers of Trikafta on the upcoming earnings call.
In August 2020, the European Commission approved Kaftrio (brand name of Trikafta in Europe).
Following the nod in the EU, about 10,000 new patients with one minimal function mutation and one F508del mutation are now eligible to be treated with Kaftrio. The drug is most likely to have contributed to revenues in the third quarter.
However, in the last reported quarter, management had stated that they will launch Kaftrio virtually in Europe during the peak of the pandemic. This, in turn, may hurt the drug’s initial uptake as patients may not be able to see their doctors for treatment initiation. Therefore, there is uncertainty about the actual rate and the level of adoption in Europe.
The strong acceptance of Trikafta caused the sales erosion of Vertex’s other CF drugs and its existing combinations, namely Kalydeco, Orkambi and Symdeko. In the last reported quarter, all the other three CF medicines saw a year-over-year decline in sales, a trend that most likely continued in the to-be-reported quarter as well.
Meanwhile, higher international revenues owing to a strong patient uptake of Orkambi and Symkevi following the completion of reimbursement arrangements in the key ex-U.S. countries like England and France in 2019, might have boosted the company’s sales in the third quarter.
Why a Likely Positive Surprise?
Our proven model predicts an earnings beat for Vertex this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Vertex has an Earnings ESP of +3.83% as the Zacks Consensus Estimate is pegged at $2.39 while the Most Accurate Estimate is pegged at $2.48.
Zacks Rank: Vertex has a Zacks Rank #3, currently.
Vertex Pharmaceuticals Incorporated Price and Consensus
Here are some other drug/biotech stocks worth considering from the same space as our model shows that these too have the right combination of elements to beat on earnings this reporting cycle.
Compugen (CGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #2, presently. The company is scheduled to report earnings on Nov 5.
Gilead Sciences (GILD - Free Report) has an Earnings ESP of +3.08% and is Zacks #3 Ranked at present. The company is scheduled to report earnings on Oct 28.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
We expect Vertex Pharmaceuticals Incorporated (VRTX - Free Report) to surpass expectations when it reports third-quarter 2020 results on Oct 29, after the market closes.
The company’s surprise record is pretty impressive with an earnings beat in each of the trailing four quarters, the average being 27.71%. In the last reported quarter, Vertex delivered an earnings surprise of 22.54%.
Shares of Vertex have lost 3.3% in the year so far compared with the industry’s 2.8% decrease.
Let’s see, how things are shaping up for the quarter to be reported.
Factors at Play
Revenue growth in the last reported quarter was driven by a rapid uptake of the company’s newly-launched cystic fibrosis (CF) medicine Trikafta, a trend that most likely continued in the third quarter as well.
Notably, first-half sales of Trikafta benefited from some early refills by patients amid COVID-19-led disruptions. This increased patient inventory is likely to have normalized in the third quarter. Also, the pace of new patient initiations of Trikafta might have slowed in the third quarter as a high percentage of currently eligible patients is already on Trikafta. Investors will be keen to know the sales numbers of Trikafta on the upcoming earnings call.
In August 2020, the European Commission approved Kaftrio (brand name of Trikafta in Europe).
Following the nod in the EU, about 10,000 new patients with one minimal function mutation and one F508del mutation are now eligible to be treated with Kaftrio. The drug is most likely to have contributed to revenues in the third quarter.
However, in the last reported quarter, management had stated that they will launch Kaftrio virtually in Europe during the peak of the pandemic. This, in turn, may hurt the drug’s initial uptake as patients may not be able to see their doctors for treatment initiation. Therefore, there is uncertainty about the actual rate and the level of adoption in Europe.
The strong acceptance of Trikafta caused the sales erosion of Vertex’s other CF drugs and its existing combinations, namely Kalydeco, Orkambi and Symdeko. In the last reported quarter, all the other three CF medicines saw a year-over-year decline in sales, a trend that most likely continued in the to-be-reported quarter as well.
Meanwhile, higher international revenues owing to a strong patient uptake of Orkambi and Symkevi following the completion of reimbursement arrangements in the key ex-U.S. countries like England and France in 2019, might have boosted the company’s sales in the third quarter.
Why a Likely Positive Surprise?
Our proven model predicts an earnings beat for Vertex this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Vertex has an Earnings ESP of +3.83% as the Zacks Consensus Estimate is pegged at $2.39 while the Most Accurate Estimate is pegged at $2.48.
Zacks Rank: Vertex has a Zacks Rank #3, currently.
Vertex Pharmaceuticals Incorporated Price and Consensus
Vertex Pharmaceuticals Incorporated price-consensus-chart | Vertex Pharmaceuticals Incorporated Quote
Other Stocks to Consider
Here are some other drug/biotech stocks worth considering from the same space as our model shows that these too have the right combination of elements to beat on earnings this reporting cycle.
Alnylam Pharmaceuticals (ALNY - Free Report) has an Earnings ESP of +4.23% and a Zacks Rank of3, currently. The company is scheduled to report earnings on Nov 5.You can see the complete list of today’s Zacks #1 Rank stocks here.
Compugen (CGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #2, presently. The company is scheduled to report earnings on Nov 5.
Gilead Sciences (GILD - Free Report) has an Earnings ESP of +3.08% and is Zacks #3 Ranked at present. The company is scheduled to report earnings on Oct 28.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>